Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. Taltz clears skin by blocking a specific protein in the body that causes inflammation, whereas Zepbound reduces body weight by mimicking natural hormones to lower appetite and calorie intake.

At 36 weeks, 27.1% of participants using the combination achieved both complete skin clearance and at least 10% weight loss, compared to only 5.8% of those using Taltz alone. This landmark study marks Taltz as the first psoriatic biologic to show a successful comprehensive treatment approach when paired with an incretin therapy for obesity.

These findings suggest that addressing obesity simultaneously with Zepbound can directly reduce the overall burden of psoriasis, which is often harder to treat in patients with higher body weight. The safety profile for the combined treatment was consistent with the known effects of each drug, with most adverse events reported as mild to moderate. Common side effects for the combination arm included nausea, diarrhea, and injection site reactions, while the Taltz-only group frequently reported nasopharyngitis and injection site reactions.

Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the US, Europe, China, Japan, and internationally.